The pCloDF13-encoded bacteriocin release protein (BRP; Mr 2,871) is essential for the translocation of cloacin DF13 across the cell envelope of producing Escherichia coli cells. Overproduction of this BRP provokes lysis (quasilysis) of cells. Construction and analysis of a hybrid BRP-(3-lactamase protein (BRP-Bla) demonstrated that the BRP contains a lipid modified cysteine residue at its amino terminus and is mainly located in the outer membrane. The significance of lipid modification for the localization and functioning of the BRP was investigated. Site-directed mutagenesis was used to substitute the cysteine residue for a glycine residue in the lipobox of the BRP and the BRP-Bla protein. The mutated BRP was unable to bring about the release of cloacin DF13 and could not provide the lysis (quasilysis) of host cells. However, the mutated BRP strongly inhibited the colony-forming ability of the cells, indicating that induction of the mutated protein still affected cell viability. In contrast to the wild-type BRP-Bla protein, the mutated BRP-Bla protein was mainly located in the cytoplasmic membrane, indicating that the mutation prevented the proper localization of the protein.
in the cytoplasmic membrane, indicating that the mutation prevented the proper localization of the protein.
The results indicated that lipid modification of the BRP is required for its localization and release of cloacin DF13, but not for its lethality to host cells.
Bacteriocin release proteins (BRPs) are low-molecularweight proteins required for the translocation for newly synthesized bacteriocin molecules across both the cytoplasmic and outer membrane of producing Escherichia coli cells. The genes encoding a certain bacteriocin and its corresponding BRP are organized in a single operon and transcribed from the same promoter, which can be induced by activation of the host cell SOS response. Moderate induction of a bacteriocin operon results in strongly increased synthesis and release of the bacteriocin, whereas strong induction leads to lysis (marked decline in culture turbidity, also called quasilysis) of host cells due to the elevated level of BRP gene expression (9, 32) .
Studies on the molecular basis of BRP-dependent bacteriocin export and cell lysis (quasilysis) have indicated that BRPs directly or indirectly activate the detergent-resistant phospholipase A, which leads to local permeabilization zones in the outer membrane and possibly also in the cytoplasmic membrane (3, 22, 34) . These zones function in the release of bacteriocins and certain other cellular proteins, but might be deleterious to the cells when present in too large amounts. The precise role of BRPs in the translocation of bacteriocins across the cytoplasmic membrane as well as their effect on the integrity of this membrane are still poorly understood.
With the exception of a pColE9-J-encoded BRP, which seems to be involved in lysis but not in colicin export (15; R. James, personal communication), all known BRPs are highly similar in primary structure (4, 6, 9, 10, 29, 40) . They contain a signal peptide with a Leu-X-Y-Cys sequence around the signal peptide cleavage site. This so-called lipobox, in which X and Y represent small neutral amino acids, is the consen-* Corresponding author. sus modification sequence for bacterial prolipoproteins (42) . In these proteins, the cysteine residue is modified with diglyceride prior to their processing by signal peptidase II (SPase II) between the Y and cysteine residue. Subsequently, a third fatty acid is covalently linked to the Nterminal cysteine.
In a previous paper (23), we described the construction of ,a hybrid protein consisting of the almost complete pCloDF13-encoded BRP (amino-terminal part) fused to the mature portion of P-lactamase (carboxyl-terminal part). This BRP-Bla hybrid protein enabled us to study the acylation, processing, and subcellular localization of the BRP. The hybrid protein was shown to be modified with diglyceride and fatty acids, processed by SPase II, and located primarily in the outer membrane of E. coli cells (about 70%), whereas the remainder was found in the cytoplasmic membrane. A similar distribution was observed in E. coli minicells, which allow the detection of the mature BRP (31) . The BRP-Bla protein can bring about the release of cloacin DF13, and overproduction of the hybrid protein leads to quasilysis of host cells (Luirink et al., submitted for publication).
In this study, we investigated the significance of lipid modification for the localization and functioning of the BRP. Site-directed mutagenesis was used to substitute the cysteine residue for a glycine residue in the lipobox of the BRP and BRP-Bla protein. The Bacterial strains, plasmids, and media. The various E. coli strains used in this study are listed in Table 1 .
Plasmids pACYC184 (5) and pJN67 (37) were used in the construction of pJL25 (see also Fig. 3 ). Plasmid pJL12, containing the BRP-Bla hybrid gene, has been described previously (23) . Plasmid pINIIIAl (25) was used for expression of the BRP and mutated BRP gene. Restriction fragments were cloned in the M13 phage vectors mp8 (26) and mpll (27) for the construction of mutations and DNA sequencing. Plasmid pPI232, encoding detergent-resistant phospholipase A, has been described before (8) .
Cells were routinely grown in Lab-Lemco broth (Oxoid Ltd., London, England) supplemented with 0.5% (wt/vol) sodium chloride and 0.5% (wt/vol) sodium lactate. When necessary, ampicillin (100 ,ug ml-'), tetracycline (15 ,ug ml-'), and/or chloramphenicol (30 ,ug (43) , using E. coli BMH71-18 mutL as primary host. Putative mutants were identified by colony probing, using the 5'-32P-labeled mutagenic primer at room temperature, followed by successive washes at increasing temperatures (43) . To confirm that only the desired mutation had taken place, the DNA sequence of the mutated DNA fragment was determined by the dideoxy termination procedure of Sanger et al. (35) , using E. coli JM103 as host for the M13 bacteriophage.
For mutagenesis of the BRP gene, a 0.4-kilobase BstNIClaI fragment of pEV67, encompassing the complete BRP gene, was subcloned in M13mp8 (21) . Following mutagenesis, the mutated BRP DNA fragment was isolated by digestion with EcoRI and HindIII; subsequently, the fragment was cloned into the polylinker of pINIIIA1.
For mutagenesis of the BRP-Bla hybrid gene, a 0.8-kilobase PstI fragment of pJL12 carrying a 5'-terminal part of the BRP-Bla hybrid gene (23) was subcloned in M13mpll. Following mutagenesis, the fragment was recloned into pJL12 lacking the PstI fragment.
Other recombinant DNA techniques. For isolation of plasmid DNA and M13 double-stranded DNA, the alkaline method of Bimboim and Doly (1) was used. Transformation of CaCl2-treated cells was performed as described by Dagert and Ehrlich (7) . All other basic DNA manipulations were carried out as described by Maniatis et al. (24) . DNAmodifying enzymes were purchased from Bethesda Research Laboratories, Inc., Bethesda, Md., and Pharmacia, Uppsala, Sweden. All enzymes were used according to the instructions of the suppliers.
Immunochemical procedures. The hybrid BRP-Bla protein was detected by immunoblotting carried out essentially as described by Towbin et al. (36) and using a rabbit antiserum raised against purified P-lactamase. The amount of cloacin DF13 in culture supernatant fractions, broken cell suspensions, and subcellular fractions was determined with an enzyme-linked immunosorbent assay as described previously (38) .
Labeling experiments. Labeling and pulse-chase labeling of whole cells and in vitro transcription/translation studies were carried out essentially as described previously (11, 23) . Immunoprecipitation was carried out by the method of Hayashi and Wu (12) , using an antiserum directed against P-lactamase. When indicated, globomycin dissolved in dimethyl sulfoxide (10 mg ml-1) was added 5 min prior to labeling (final concentration, 100 ,ug ml-') to prevent processing by SPase II (13) . Samples were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE; 20) and autoradiography.
Subcellular localization. For isolation of subcellular fractions, cells were converted to spheroplasts essentially as described by Witholt et al. (41) . Spheroplasts were collected by centrifugation, and the supematant was taken as the periplasmic fraction. Subsequently, the spheroplasts were broken by short periods of sonication, and the membranes (cytoplasmic and outer membranes) were collected by centrifugation. This fraction was taken as the total membrane fraction. The supernatant fraction contained the cytoplasmic fraction. Cytoplasmic and outer membranes were separated and isolated by isopycnic sucrose density gradient essentially as described by Osborn et al. (30) . After centrifugation, the sucrose density of each fraction was determined and samples of the various sucrose gradient fractions were analyzed by SDS-PAGE to examine the distribution of cytoplasmic and outer membrane proteins.
The presence of mutant and wild-type BRP-Bla protein in each fraction was determined by measuring the P-lactamase activity and by immunoblotting; 3-lactamase activity was assayed spectrophotometrically as described by O'Callaghan et al. (28) . Proteins present in periplasmic, cytoplasmic, and medium fractions were concentrated by trichloroacetic acid precipitation and washed with 90% ethanol prior to analysis by SDS-PAGE and immunoblotting. The level of ampicillin resistance of cells was measured by a plate assay as described by Broome-Smith and Spratt (2) or a tube assay as described by Kadonaga et al. (16) .
RESULTS
Construction of mutant BRP and mutant BRP-Bla. The amino-terminal cysteine residue of the mature portion of the pCloDF13-encoded BRP is modified with diglyceride and fatty acids. To mutation was introduced in the BRP gene by site-directed mutagenesis. The cysteine residue in the consensus sequence for prolipoprotein modification and processing was converted into a glycine residue (Fig. 1) . Subsequently, the mutant BRP gene was subcloned under control of the Ipp-lac promoter-operator system in the polylinker of the expression vector pINIIIAL. The resulting plasmid was designated pJL18. The wild-type BRP gene was cloned in an identical manner, which resulted in plasmid pJL17.
To examine the effects of the mutation of Cys+1 to Gly+' on modification, processing, and subcellular localization, the BRP-Bla hybrid gene, contained in pJL12, was mutated in the same way as the BRP gene (Fig. 1) (Fig. 2B) . Colony formation appeared to be inhibited, indicating that expression of the mutant BRP is potentially a lethal event. The wild-type BRP encoded by pJL17 showed a strong effect on colony-forming ability, probably due to lysis of induced cells (Fig. 2B) . These (Fig. 3) vector. Plasmid pJL25 was transferred to E. coli FTP4170. With this recombinant strain, a high yield of cloacin DF13 production was obtained upon induction of the bacteriocin promoter with mitomycin C without concomitant lysis of host cells, due to the absence of the BRP gene. A double transformant of strain FTP4170, harboring both pJL18 and pJL25, was used to study the effects of simultaneous induction of BRP and cloacin DF13 synthesis on cell growth and bacteriocin release. BRP synthesis was induced with IPTG, whereas the synthesis of cloacin DF13 was strongly induced with 500 ng of mitomycin C ml-' ( Table 2 ). The results showed that high induction of the mutant BRP gene did not result in the release of cloacin DF13, nor did it affect cell growth. In contrast, moderate induction of the wild-type BRP gene was sufficient for significant release of cloacin DF13 without apparent cell lysis.
Synthesis and processing of the mutant BRP-Bla. The synthesis and processing of the pCloDF13-encoded BRP is difficult to study in whole cells of E. coli due to its low molecular mass, which makes it almost impossible to visualize the polypeptide. Therefore, the effect of the Cys+'-*Gly+l mutation on synthesis and processing was studied with the mutant BRP-Bla hybrid protein (see also reference 23). Cells of E. coli N3406 harboring pJL12 or pJL16 were labeled in the presence and absence of globomycin, and the immunoprecipitated hybrid proteins were analyzed by SDS-PAGE (Fig. 4A ). When cells with pJL12 were labeled with [35S]methionine, the mature form of the hybrid protein was easily identified (lane 1). After labeling in the presence of globomycin, the precursor of the hybrid protein was detected, as expected (lane 2; see also reference 23). This precursor migrated as a double band (23; see below). In contrast, following labeling in the presence and absence of globomycin, the mutant hybrid protein was detected as a double band (lanes 3 and 4) First, in vitro transcription/translation studies were carried out with pJL12 and pJL16 (Fig. 4B) . Both the BRP-Bla and the mutant hybrid proteins migrated at the position of the precursor of the wild-type hybrid protein. Both proteins still migrated as a double band. Since processing of precursors does not take place in this type of in vitro experiment, this indicated that there is no precursor-product relationship between the two counterparts of the doublet bands.
Second, a pulse-chase experiment was carried out at 30°C (Fig. 4C) . The precursor of the BRP-Bla protein was detected after pulse-labeling for 15 s and was chased into the mature form (lanes 8 through 12) . In contrast, the precursor of the mutant hybrid protein could not be chased into a mature form (lanes 13 through 17) . Also, a comparable pulse-chase experiment was carried out at 37°C, in which the chase period was extended up to 10 min. Virtually the same results were obtained (not shown).
Taken together, the results indicated that the mutation prevented processing of the precursor of the hybrid protein.
Apparently, SPase II does not recognize the mutated signal peptide cleavage site anymore, and alternative processing by, for instance, SPase I does not occur.
Subcellular localization. In a previous paper the subcellular localization of the BRP-Bla hybrid protein was studied (23) . About 70% of the protein was detected in the outer membranes and the remainder was mainly located in the cytoplasmic membrane, whereas minor amounts were found in the periplasm and cytoplasm. This localization was in agreement with the localization of the BRP studied in E. coli minicells (31) . Cells expressing the hybrid protein were resistant to ampicillin, indicating that the P-lactamase portion of the fusion protein protruded into the periplasm (23) .
The localization of the mutant BRP-Bla protein was studied by determining the ,-lactamase activity of subcellular fractions of strain N3406(pJL16) and by immunoblotting.
About 70% of the total 3-lactamase activity was located in the total membrane fraction, whereas, in contrast to the wild-type BRP-Bla protein, a significant P-lactamase activity (about 30% of the total activity) was detected in the periplasmic fraction. When the total membrane fraction was separated into cytoplasmic and outer membrane fractions, most of the activity (about 90%) was found to be associated with the cytoplasmic membranes, whereas the wild-type BRP-Bla protein was mostly found in the outer membranes (about 75%; Fig. 5 ). This distribution was confirmed by immunoblotting of pooled membrane fractions (Fig. 6) . These experiments showed that the mutation prevented the proper localization of the hybrid protein.
The mutant hybrid protein could not be detected in the periplasm by immunoblotting (not shown). Possibly, the P-lactamase activity found in the periplasmic fraction is derived from unstable ,B-lactamase fragments generated by proteolytic degradation of mutant hybrid proteins.
The During the course of our study, Cavard et al. (3) and Pugsley and Cole (33) used site-directed mutagenesis to change the lipobox of the pColA-and pColE2-encoded BRPs (Cal and CelB), respectively. Cavard et al. (3) replaced the cysteine at the + 1 position for a threonine and the alanine at the -1 position for a proline in two different constructs. Both mutations prevented normal modification and processing, and the mutant BRPs proved not to be functional in outer membrane detergent-resistant phospholipase A-dependent lysis and export of colicin A. Pugsley and Cole (33) substituted the cysteine at the + 1 position of the pColE2 BRP for an arginine. This mutation prevented processing of the pColE2-encoded BRP precursor. However, this mutant protein was able to stimulate the export of colicin E2, albeit to a lesser extent, and it caused a delayed phospholipase A-dependent lysis of cells.
In this study, the NH2-terminal cysteine residue of the pCloDF13-encoded BRP was changed into a glycine residue by oligonucleotide-directed mutagenesis and the effects of this mutation on the functioning of the BRP were investigated. Furthermore, the same mutation was created in the BRP-Bla hybrid gene to facilitate the study of the effects of modification on processing and subcellular localization. The experiments showed that the mutant BRP was not functional with respect to release of cloacin DF13 and lysis of host cells. These results agree mostly with those obtained by Cavard and co-workers. However, induction of the mutant BRP gene caused lethality of host cells as observed after growing of induced cells on broth agar plates, but this lethality was found to be independent of detergent-resistant phospholipase A.
In contrast to the wild-type BRP-Bla protein, the mutant BRP-Bla protein was not processed. We assume that the constructed mutation prevents processing of the mutant BRP by SPase II and also by SPase I, despite the creation of the putative SPase I cleavage site Ala-Gly (39) . Alternative processing by SPase I has been shown to take place with one of the mutant pColA BRPs (Cys+'-*Thr+1). The mutant pColE2 BRP was not processed either, despite the suitable SPase I cleavage site created in this protein (39) .
Expression of the mutant BRP-Bla protein resulted in a doublet protein band migrating slightly faster than the wildtype BRP-Bla precursor. Both bands of the doublet represented the mutant precursor as confirmed by pulse-chase experiments and in vitro transcription/translation studies. The formation of doublet bands is not an unusual feature for (mutant) pre-p-lactamase and is believed to be the result of differences in conformation (18) .
Most of the mutant BRP-Bla precursor protein was found to be associated with the cytoplasmic membranes. This is in contrast to the wild-type mature BRP-Bla protein which is mainly located in the outer membranes. Unfortunately, expression of the hybrid BRP-Bla gene is too low to confirm these results by immunoelectron microscopy studies (23) . However, we feel that the data obtained by "conventional" fractionation methods are reliable, taking the very low abundance of the hybrid proteins into account. The most plausible explanation for the aberrant localization of the mutant hybrid protein is that the uncleaved signal sequence anchors the protein in the cytoplasmic membrane, as has been observed earlier for uncleaved pre-p-lactamase (17, 18) . Like the ,-lactamase portion of the wild-type BRP-Bla protein (23) , the ,-lactamase portion of the mutant hybrid protein probably protrudes into the periplasm since this protein is fully active in the protection of cells against ampicillin. Cytoplasmic (pre) P-lactamase is enzymatically inactive (16) .
We assume that the results obtained with the mutant BRP-Bla hybrid protein can be extrapolated to the mutant BRP. Therefore, the lack of processing and the aberrant subcellular localization might explain why this protein is unable to bring about the release of cloacin DF13 and lysis of cells.
The pCloDF13-encoded BRP possesses three functions that can be distinguished. It can bring about the release of cloacin DF13, it can cause a marked decline in culture turbidity (lysis) in liquid medium, and it inhibits colony formation of induced host cells on solid medium. Based on our results and those of others (3, 33) , we assume that the lipid moiety is essential for targeting of the BRP to the outer membrane and that the mature polypeptide structure is required for activation of the detergent-resistant phospholipase A. Furthermore, the lethality (inhibition of colony formation) caused by the BRP is a phospholipase-independent effect which might involve the BRP signal sequence. Lipid modification does not seem to be essential for proper localization and functioning of the pColE2-encoded BRP (33) . Possibly, the peptide part of this BRP also has affinity for the outer membrane as suggested for unmodified Braun's prolipoprotein (14) . The BRP signal sequence, which seems to be extremely stable for the pColA-and pColE2-encoded BRPs, could play a role in killing of host cells. The accumulation of this sequence or the interaction between the signal sequence and the cytoplasmic membrane or both could be deleterious to the cells. Recently, we observed that a mutant BRP, containing only four amino-terminal amino acid residues, still causes lethality of host cells on plates, but is unable to cause lysis of cells in liquid medium and to bring about release of cloacin DF13 (submitted for publication). We are currently investigating the role of the pCloDF13 BRP signal sequence in more detail by fusing it directly to the mature part of ,-lactamase.
